Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCPNASDAQ:HOWLNASDAQ:IRDNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.55-2.5%$1.51$1.12▼$3.26N/A2.1526,677 shs13,161 shsHOWLWerewolf Therapeutics$1.24+2.5%$1.06$0.60▼$4.18$55.64M0.66441,049 shs249,646 shsIRDOpus Genetics$0.93+1.1%$0.93$0.65▼$1.75$55.56MN/A476,494 shs184,159 shsQNTMQuantum Biopharma$30.18+17.3%$11.18$2.70▼$34.30$87.75M0.55943,013 shs644,328 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%+0.65%+2.31%-0.64%-37.75%HOWLWerewolf Therapeutics0.00%-3.88%+8.77%+9.73%-57.09%IRDOpus Genetics0.00%-6.21%-6.44%-26.19%+92,999,900.00%QNTMQuantum Biopharma0.00%+58.84%+164.97%+433.22%+3,017,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCPCocrystal Pharma1.7545 of 5 stars3.53.00.00.00.61.70.0HOWLWerewolf Therapeutics3.2468 of 5 stars3.53.00.00.01.15.00.6IRDOpus Genetics1.2655 of 5 stars3.50.00.00.00.60.00.6QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 3.00Buy$7.00351.61% UpsideHOWLWerewolf Therapeutics 3.00Buy$8.33572.04% UpsideIRDOpus Genetics 3.00Buy$7.33688.53% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest COCP, HOWL, QNTM, and IRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.004/11/2025IRDOpus GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/1/2025IRDOpus GeneticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.004/1/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/AHOWLWerewolf Therapeutics$1.88M29.60N/AN/A$1.65 per share0.75IRDOpus Genetics$10.99M5.05N/AN/A$0.21 per share4.43QNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)IRDOpus Genetics-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)QNTMQuantum Biopharma-$14.20M-$15.98N/AN/AN/AN/A-155.20%-94.90%8/13/2025 (Estimated)Latest COCP, HOWL, QNTM, and IRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A3/31/2025Q4 2024IRDOpus Genetics-$0.34-$1.27-$0.93-$1.27$11.10 million$3.40 million3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A4.574.57HOWLWerewolf Therapeutics0.468.098.09IRDOpus GeneticsN/A1.981.98QNTMQuantum BiopharmaN/A0.960.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%HOWLWerewolf Therapeutics64.84%IRDOpus Genetics14.97%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%HOWLWerewolf Therapeutics23.60%IRDOpus Genetics6.60%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma10N/AN/ANot OptionableHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionableIRDOpus Genetics1459.66 million55.72 millionN/AQNTMQuantum BiopharmaN/A2.91 million2.48 millionN/ACOCP, HOWL, QNTM, and IRD HeadlinesRecent News About These CompaniesUnbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)June 19 at 7:31 PM | morningstar.comQuantum, CyberCatch, Kodiak at 52-Week Highs on NewsJune 18 at 4:07 PM | ca.finance.yahoo.comSingular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline ProgressJune 18 at 9:19 AM | newsfilecorp.comKeg, LQWD, Quantum at 52-Week Highs on NewsJune 17 at 3:51 PM | baystreet.caCannabis Stocks To Add to Your Watchlist - June 17thJune 17 at 2:22 PM | marketbeat.comQuantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJune 17 at 8:00 AM | globenewswire.comQuantum BioPharma plans special dividend tied to legal actionJune 14, 2025 | investing.comBest Cannabis Stocks To Add to Your Watchlist - June 13thJune 13, 2025 | marketbeat.comQuantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement ProceedsJune 13, 2025 | globenewswire.comQuantum BioPharma Boosts Digital Asset Holdings to $5 Million with New Bitcoin PurchaseJune 10, 2025 | bitcoinmagazine.comQuantum BioPharma clarifies misinformation on stock name, RTO rumorsJune 4, 2025 | investing.comQuantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd WellnessJune 4, 2025 | nasdaq.comQuantum BioPharma Clarifies It Has Not Changed Its NameJune 3, 2025 | globenewswire.comiNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS PatientsJune 2, 2025 | globenewswire.comQuantum BioPharma settles disputes with former CEOJune 1, 2025 | uk.investing.comWhat's Going On With Quantum Biopharma Stock Today?May 30, 2025 | benzinga.comQuantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza BokhariMay 30, 2025 | globenewswire.comQuantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.May 29, 2025 | globenewswire.comQuantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation SyndromeMay 28, 2025 | globenewswire.comQuantum BioPharma Increases Crypto Holdings To $4.5 Mln For Strategic GrowthMay 21, 2025 | nasdaq.comQuantum BioPharma Partners with BitGo to Securely Store its Crypto Currency AssetsMay 21, 2025 | thestar.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, HOWL, QNTM, and IRD Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.55 -0.04 (-2.52%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.60 +0.05 (+3.48%) As of 06/18/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Werewolf Therapeutics NASDAQ:HOWL$1.24 +0.03 (+2.48%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.28 +0.04 (+3.15%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Opus Genetics NASDAQ:IRD$0.93 +0.01 (+1.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.93 +0.00 (+0.32%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Quantum Biopharma NASDAQ:QNTM$30.18 +4.45 (+17.29%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$34.05 +3.87 (+12.82%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
